Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Prima posts big gain on CVac's survival trend

Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD) surged $4.31 (269%) to $5.91 on NASDAQ on Wednesday after reporting final subset analyses from a Phase II ovarian

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE